Los Angeles Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Los Angeles Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-41,917	Closed	-$348K	–	1379
2014 Q1	$348K	Sell	41,917 -4,945	-11%	-$42.4K	﹤0.01%	1011
2013 Q4	$396K	Sell	46,862 -760	-2%	-$6.41K	﹤0.01%	995
2013 Q3	$380K	Buy	47,622 +930	+2%	+$7.48K	﹤0.01%	1012
2013 Q2	$360K	Buy	+46,692	New	+$364K	0.01%	1020

Other funds holding PDLI

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Los Angeles Capital Management's PDLI Position: Q2 2014 in Review

Los Angeles Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q2 2014, closing a stake of 41,917 shares — an estimated $348K sold.

Los Angeles Capital Management first reported a position in PDLI in Q2 2013 and held it in 4 quarters. The position peaked at $396K in Q4 2013. 222 funds tracked by Wall St. Rank hold PDLI as of Q2 2014.

Los Angeles Capital Management reported no remaining PDL BioPharma, Inc. position as of Q2 2014 after selling out during the quarter.
Los Angeles Capital Management sold 41,917 PDL BioPharma, Inc. shares in Q2 2014, an estimated $348K.
Los Angeles Capital Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 4 quarters.
Los Angeles Capital Management's PDL BioPharma, Inc. position peaked at $396K in Q4 2013.
222 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q2 2014.

Based on Los Angeles Capital Management's 13F filing for Q2 2014, filed 12 Aug 2014.